“
TL;DR
This study analyzed 5-year patient data from a case-control analysis of 227 patients with unilateral nAMD receiving oral zeaxanthin (20 mg/day) supplementation.
Ophthalmology and Therapy · 4 authors, 5 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This study analyzed 5-year patient data from a case-control analysis of 227 patients with unilateral nAMD receiving oral zeaxanthin (20 mg/day) supplementation.
This study analyzed 5-year patient data from a case-control analysis of 227 patients with unilateral nAMD receiving oral zeaxanthin (20 mg/day) supplementation. The primary finding was a significantly lower 5-year cumulative incidence of fellow-eye nAMD conversion in the zeaxanthin group (22%) compared to a historical control group (48%, p < 0.0001). Cost-utility and cost-benefit analyses were performed using an 11-year model. The model estimated a 0.42 quality-adjusted life-year (QALY) gain and 3 months of life saved per patient, resulting in dominant cost-utility ratios. Limitations include the use of historical controls rather than a randomized comparator, the exclusive use of bevacizumab as the anti-VEGF agent, and uncertainty about the impact of concurrent AREDS2 supplements. The authors conclude that long-term oral zeaxanthin supplementation for unilateral nAMD is effective at reducing fellow-eye disease conversion and is highly cost-effective.